Identification of a novel family of BRAF V600E inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5220-5230

  Qin, Jie ^a   Xie, Peng ^a   Ventocilla, Christian ^a   Zhou, Guoqiang ^a   Vultur, Adina ^a   Chen, Quan ^a   Liu, Qin ^a   Herlyn, Meenhard ^a   Winkler, Jeffrey ^a   Marmorstein, Ronen ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NAPHTHOL DERIVATIVE; QUINOLONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTRACELLULAR SIGNALING; MELANOMA CELL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYDROQUINONES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; NAPHTHOLS; PROTO-ONCOGENE PROTEINS B-RAF; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862273387     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3004416     Document Type: Article

References (33)

1. Wellbrock, C.; Karasarides, M.; Marais, R. The RAF proteins take centre stage Nat. Rev. Mol. Cell. Biol. 2004, 5, 875-885
2. Wojnowski, L.; Stancato, L. F.; Larner, A. C.; Rapp, U. R.; Zimmer, A. Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis Mech. Dev. 2000, 91, 97-104
3. Jaiswal, R. K.; Moodie, S. A.; Wolfman, A.; Landreth, G. E. The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras Mol. Cell. Biol. 1994, 14, 6944-6953
4. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer Nature 2002, 417, 949-954
5. Greenman, C.; Stephens, P.; Smith, R.; Dalgliesh, G. L.; Hunter, C.; Bignell, G.; Davies, H.; Teague, J.; Butler, A.; Stevens, C.; Edkins, S.; O'Meara, S.; Vastrik, I.; Schmidt, E. E.; Avis, T.; Barthorpe, S.; Bhamra, G.; Buck, G.; Choudhury, B.; Clements, J.; Cole, J.; Dicks, E.; Forbes, S.; Gray, K.; Halliday, K.; Harrison, R.; Hills, K.; Hinton, J.; Jenkinson, A.; Jones, D.; Menzies, A.; Mironenko, T.; Perry, J.; Raine, K.; Richardson, D.; Shepherd, R.; Small, A.; Tofts, C.; Varian, J.; Webb, T.; West, S.; Widaa, S.; Yates, A.; Cahill, D. P.; Louis, D. N.; Goldstraw, P.; Nicholson, A. G.; Brasseur, F.; Looijenga, L.; Weber, B. L.; Chiew, Y. E.; DeFazio, A.; Greaves, M. F.; Green, A. R.; Campbell, P.; Birney, E.; Easton, D. F.; Chenevix-Trench, G.; Tan, M. H.; Khoo, S. K.; Teh, B. T.; Yuen, S. T.; Leung, S. Y.; Wooster, R.; Futreal, P. A.; Stratton, M. R. Patterns of somatic mutation in human cancer genomes Nature 2007, 446, 153-158
6. Ikenoue, T.; Hikiba, Y.; Kanai, F.; Tanaka, Y.; Imamura, J.; Imamura, T.; Ohta, M.; Ijichi, H.; Tateishi, K.; Kawakami, T.; Aragaki, J.; Matsumura, M.; Kawabe, T.; Omata, M. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors Cancer Res. 2003, 63, 8132-8137
7. Satyamoorthy, K.; Li, G.; Gerrero, M. R.; Brose, M. S.; Volpe, P.; Weber, B. L.; Van Belle, P.; Elder, D. E.; Herlyn, M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation Cancer Res. 2003, 63, 756-759
8. Dienstmann, R.; Tabernero, J. BRAF as a target for cancer therapy Anticancer Agents Med. Chem. 2011, 11, 285-295
9. Finn, L.; Markovic, S. N.; Joseph, R. W. Therapy for metastatic melanoma: the past, present, and future BMC Med. 2012, 10, 23
10. Zambon, A.; Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Marais, R.; Springer, C. J. Small molecule inhibitors of BRAF in clinical trials Bioorg. Med. Chem. Lett. 2012, 22, 789-792
11. Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Project, C. G.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-Raf Cell 2004, 116, 855-867
12. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 2011, 364, 2507-2516
13. Poulikakos, P. I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M. T.; Salton, M.; Dahlman, K. B.; Tadi, M.; Wargo, J. A.; Flaherty, K. T.; Kelley, M. C.; Misteli, T.; Chapman, P. B.; Sosman, J. A.; Graeber, T. G.; Ribas, A.; Lo, R. S.; Rosen, N.; Solit, D. B. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 2011, 480, 387-390
14. Villanueva, J.; Vultur, A.; Herlyn, M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options Cancer Res. 2011, 71, 7137-7140
15. Niculescu-Duvaz, I.; Roman, E.; Whittaker, S. R.; Friedlos, F.; Kirk, R.; Scanlon, I. J.; Davies, L. C.; Niculescu-Duvaz, D.; Marais, R.; Springer, C. J. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead J. Med. Chem. 2006, 49, 407-416
16. Luo, C.; Xie, P.; Marmorstein, R. Identification of BRAF inhibitors through in silico screening J. Med. Chem. 2008, 51, 6121-6127
17. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
18. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S.; Fong, D.; Zhu, Y. L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S. H.; Schlessinger, J.; Zhang, K. Y.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3041-3046
19. Xie, P.; Streu, C.; Qin, J.; Bregman, H.; Pagano, N.; Meggers, E.; Marmorstein, R. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase Biochemistry 2009, 48, 5187-5198
20. Heidorn, S. J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J. S.; Springer, C. J.; Pritchard, C.; Marais, R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 2010, 140, 209-221
21. Poulikakos, P. I.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 2010, 464, 427-430
22. project, C. c.;, n. The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D 1994, 50, 760-763
23. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025
24. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr. 2004, 60, 2126-2132
25. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination Acta Crystallogr., Sect. D 1998, 54, 905-921
26. Lawrence, H.; Ge, Y.; Sebti, S. M.; Guida, W. Proteasome Inhibitors for Selectively Inducing Apoptosis in Cancer Cells. US Patent 20110201609, 2010.
27. Sucunza, D.; Dembkowski, D.; Neufeind, S.; Velder, J.; Lex, J.; Schmalz, H. G. Synthesis of a mumbaistatin analogue through cross-coupling Synlett 2007, 16, 2569-2573
28. Brimble, M. A.; Bachu, P.; Spery, J. Enantioselective synthesis of an analogue of nanaomycin A Synthesis 2007, 18, 2887-2893
29. Xie, P.; Williams, D. S.; Atilla-Gokcumen, G. E.; Milk, L.; Xiao, M.; Smalley, K. S.; Herlyn, M.; Meggers, E.; Marmorstein, R. Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity ACS Chem. Biol. 2008, 3, 305-316
30. Fang, D.; Nguyen, T. K.; Leishear, K.; Finko, R.; Kulp, A. N.; Hotz, S.; Van Belle, P. A.; Xu, X.; Elder, D. E.; Herlyn, M. A tumorigenic subpopulation with stem cell properties in melanomas Cancer Res. 2005, 65, 9328-37
31. Hsu, M. Y.; Shih, D. T.; Meier, F. E.; Van Belle, P.; Hsu, J. Y.; Elder, D. E.; Buck, C. A.; Herlyn, M. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma Am. J. Pathol. 1998, 153, 1435-1442
32. Vultur, A.; Buettner, R.; Kowolik, C.; Liang, W.; Smith, D.; Boschelli, F.; Jove, R. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells Mol. Cancer Ther. 2008, 7, 1185-1194
33. Krissinel, E.; Henrick, K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions Acta Crystallogr. 2004, 60, 2256-2268